GlobalData's report, "Candidiasis - Drug Pipeline Analysis and Market Forecasts to 2016", provides an essential source of information and analysis on the global candidiasis market. The report identifies the key trends shaping and driving the global candidiasis market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData forecasts the global candidiasis market to reach $2,386m by 2016. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

Scope

The scope of the report includes:

• Annualized global candidiasis market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report are the United States (the US), the United Kingdom (the UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include monoclonal antibodies, cytochrome inhibitors, combination therapies, aminio acid sequences and antimicrobial peptides, selective immune response amplifiers, vaccines and protein synthesis inhibitors.
• Analysis of the current and future market competition in the global candidiasis market. The key market players covered Neutec Pharma PLC (a wholly owned subsidiary of Novartis AG), Novartis AG, Demegen, Inc. and Basilea Pharmaceutica Ltd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future candidiasis market.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global candidiasis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global candidiasis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global candidiasis market landscape? – Identify, understand and capitalize.

1 Table of contents 3

• 1.1 List of Tables 5
• 1.2 List of Figures 5

2 Candidiasis : Market Characterization 6

• 2.1 Overview 6
• 2.2 Candidiasis Market Size 6
• 2.3 Candidiasis Market Forecast and Compound Annual Growth Rate 6
• 2.4 Drivers and Barriers for the Candidiasis Market 7
  • 2.4.1 Drivers for the Candidiasis Market 7
  • 2.4.2 Barriers for the Candidiasis Market 8
• 2.5 Opportunity and Unmet Need 8
• 2.6 Key Takeaway 9

3 Global Candidiasis Market: Competitive Assessment 10

• 3.1 Overview 10
• 3.2 Strategic Competitor Assessment 10
• 3.3 Product Profiles of the Major Marketed Products in Candidiasis Market - Azole Group 11
  • 3.3.1 Fluconazole 11
  • 3.3.2 Itraconazole (Oral Solution) 13
  • 3.3.3 Miconazole 14
  • 3.3.4 Clotrimazole 16
  • 3.3.5 Ketoconazole 16
• 3.4 Product Profiles of the Major Marketed Products in the Candidiasis Market – Echinocandins Class 17
  • 3.4.1 Anidulafungin (Eraxis) 17
  • 3.4.2 Micafungin 19
• 3.5 Product Profiles of the Major Marketed Products in Candidiasis Market – Polyene class 22
  • 3.5.1 Nystatin (Oral Suspension) 22
• 3.6 Key Takeaway 23

4 Global Candidiasis Market: Pipeline Assessment 24

• 4.1 Overview 24
• 4.2 Strategic Pipeline Assessment 24
  • 4.2.1 Technology Trends Analytic Framework 24
• 4.3 Candidiasis Market – Promising Drugs under Clinical Development 26
• 4.4 Molecule Profile for Promising Drugs under Clinical Development 26
  • 4.4.1 Mycograb (Efungumab) 26
  • 4.4.2 Isavuconazole 27
• 4.5 Candidiasis Therapeutics Market – Clinical Pipeline by Mechanism of Action 28
• 4.6 Candidiasis Pipeline – Pipeline by Clinical Phases of Development 28
  • 4.6.1 Candidiasis – Regulatory Filing and Phase III Clinical Pipeline 29
  • 4.6.2 Candidiasis –Phase II Clinical Pipeline 29
  • 4.6.3 Candidiasis Market – Phase I Clinical Pipeline 29
• 4.7 Key Takeaway 29

5 Global Candidiasis Market: Implications for Future Market Competition 30

6 Global Candidiasis Market: Future Players in Candidiasis Market 32

• 6.1 Introduction 32
• 6.2 Neutec Pharma PLC 32
  • 6.2.1 Overview 32
  • 6.2.2 Business Description 32
  • 6.2.3 Infectious Disease Pipeline Product Portfolio 33
  • 6.2.4 Candidiasis Product Portfolio 33
• 6.3 Novartis AG 34
  • 6.3.1 Overview 34
  • 6.3.2 Business Description 34
  • 6.3.3 Infectious Disease Pipeline Product Portfolio 35
  • 6.3.4 Candidiasis Product Portfolio 35
• 6.4 Demegen, Inc. 35
  • 6.4.1 Overview 35
  • 6.4.2 Business Description 35
  • 6.4.3 Infectious Disease Pipeline Product Portfolio 35
  • 6.4.4 Candidiasis Product Portfolio 36
• 6.5 Basilea Pharmaceutica Ltd. 36
  • 6.5.1 Overview 36
  • 6.5.2 Business Description 36
  • 6.5.3 Infectious Disease Pipeline Product Portfolio 36
  • 6.5.4 Candidiasis Product Portfolio 36

7 Candidiasis Market: Appendix 38

• 7.1 Market Definitions 38
• 7.2 Abbreviations 38
• 7.3 Research Methodology 38
  • 7.3.1 Coverage 39
  • 7.3.2 Secondary Research 39
  • 7.3.3 Forecasting 40
  • 7.3.4 Primary Research 43
  • 7.3.5 Expert Panel Validation 43
• 7.4 Contact Us 43
• 7.5 Disclaimer 43
• 7.6 Sources 44